Phase 2 Advanced/Metastatic Clinical Trials
17 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–17 of 17 trials
Recruiting
Phase 1Phase 2
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced/Metastatic Solid Tumors
Crescent Biopharma, Inc.290 enrolled17 locationsNCT07335497
Recruiting
Phase 2
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Advanced/Metastatic Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals300 enrolled10 locationsNCT07154290
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Non-small Cell Lung CancerAdvanced/Metastatic
Beijing Biotech60 enrolled1 locationNCT07641023
Recruiting
Phase 1Phase 2
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungAdvanced/Metastatic Non-Small Cell Lung Cancer
Pfizer162 enrolled45 locationsNCT07227298
Recruiting
Phase 1Phase 2
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Urothelial CarcinomaUrothelial CancerAdvanced/Metastatic Urothelial Cancer
Pfizer132 enrolled50 locationsNCT07421700
Recruiting
Phase 1Phase 2
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors
Shandong Suncadia Medicine Co., Ltd.120 enrolled2 locationsNCT06922357
Recruiting
Phase 2
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
HER2-positive Metastatic Breast CancerAdvanced/Metastatic Breast Cancer
Sun Yat-sen University57 enrolled1 locationNCT07610720
Recruiting
Phase 2
Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
Soft Tissue SarcomaPembrolizumabPhase 2+2 more
M.D. Anderson Cancer Center20 enrolled1 locationNCT07283731
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Triple-Negative Breast CancerHER2-positive Breast CancerBreast Cancer (Advanced/Metastatic)
Beijing Biotech60 enrolled1 locationNCT07510802
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Non-small Cell Lung CancerAdvanced/Metastatic NSCLC
Beijing Biotech48 enrolled1 locationNCT07467863
Recruiting
Phase 1Phase 2
Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors
CSPC Megalith Biopharmaceutical Co.,Ltd.820 enrolled1 locationNCT07415863
Recruiting
Phase 1Phase 2
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Advanced/Metastatic Solid Tumors
Adagene Inc186 enrolled21 locationsNCT05405595
Recruiting
Phase 2
Impact of Circadian Rhythm on Immunotherapy
Advanced/Metastatic NSCLC
Liza Villaruz, MD350 enrolled1 locationNCT07224971
Recruiting
Phase 1Phase 2
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
Advanced/Metastatic Solid Tumors
Qilu Pharmaceutical Co., Ltd.515 enrolled1 locationNCT07102004
Recruiting
Phase 1Phase 2
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Yonsei University44 enrolled1 locationNCT05749900
Recruiting
Phase 1Phase 2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Colorectal, CancerEsophageal CancerGastric Cancer+5 more
Merus B.V.523 enrolled45 locationsNCT03526835
Recruiting
Phase 1Phase 2
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
Locally Advanced/Metastatic Solid Tumors
Shanghai HyaMab Biotech Co.,Ltd.120 enrolled1 locationNCT05801237